References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2017-4-56-51

mrj-796

Research Article

ОБЗОРЫ

REVIEWS

Абатацепт и риск сердечно-сосудистых осложнений при ревматоидном артрите: современные данные

Abatacept and cardiovascular risk in rheumatoid arthritis: update

Попкова

Т. В.

Popkova

T. V.

popkovatv@mail.ru

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой», МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian Federation

2017

06012018

1145651

2018

Попкова Т.В.

Popkova T.V.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/796

Одной из основных причин летальности при ревматоидном артрите (РА) являются сердечно-сосудистые осложнения (ССО) – инфаркт миокарда (ИМ), инсульт и внезапная сердечная смерть, – обусловленные ранним развитием и быстрым прогрессированием атеросклероза сосудов. Показано, что при РА возникновение атеросклероза и его клинических проявлений обусловлено традиционными факторами риска (ТФР) и иммуновоспалительными механизмами, лежащими в основе патогенеза этих заболеваний. Поскольку ключевая роль в развитии атеросклероза и связанных с ним ССО при РА принадлежит хроническому воспалению и аутоиммунным нарушениям, важное место в их профилактике занимает эффективная противовоспалительная терапия. В обзоре представлены современные данные о влиянии абатацепта на общую летальность и ССО, ТФР сердечно-сосудистых заболеваний, клинические и субклинические проявления атеросклероза при РА.

Cardiovascular events (CVEs), such as myocardial infarction, stroke, and sudden cardiac death, which are due to the early development and rapid progression of atherosclerosis, are one of the main causes of mortality in rheumatoid arthritis (RA). Traditional risk factors (TRFs) and immunoinflammatory mechanisms underlying the pathogenesis of these diseases are shown to be responsible for atherosclerosis and its clinical manifestations in RA. Since the key role in the development of atherosclerosis and related CVEs in RA is played by chronic inflammation and autoimmune disorders, effective anti-inflammatory therapy occupies an important place in the prevention of the latter. The review gives an update on the effect of abatacept on overall mortality and CVEs, TRFs for cardiovascular disease, and the clinical and subclinical manifestations of atherosclerosis in RA.

сердечно-сосудистый рискревматоидный артритгенно-инженерные биологические препаратыабатацепт

cardiovascular riskrheumatoid arthritisbiological agentsabatacept

References1

Попкова ТВ, Новикова ДС, Насонов ЕЛ. Атеросклероз при ревматических заболеваниях. В кн.: Ревматология: клинические рекомендации. Mосква: Гэотар Медиа; 2010. С. 678-702. [Popkova TV, Novikova DS, Nasonov EL. Atherosclerosis in rheumatic diseases. In: Revmatologiya: klinicheskie rekomendatsii [Rheumatology: clinical guidelines]. Moscow: Geotar Media; 2010. P. 678-702.]

Peters MJ, Symmons DP, McCarey DW, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis – TASK FORCE «Cardiovascular risk management in RA». Ann Rheum Dis. 2010 Feb;69(2):325-31. doi: 10.1136/ard.2009.113696. Epub 2009 Sep 22.

Meune C, Touze E, Trinquart L, et al. High risk of clinical cardiovascular events in RA: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010 Apr;103(4):253-61. doi: 10.1016/j. acvd.2010.03.007. Epub 2010 May 18.

MeuneC, Touze E, Trinqurte L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology (Oxford). 2009 Oct; 48(10):1309-13. doi: 10.1093/rheumatology/ kep252. Epub 2009 Aug 20.

Van Halm VP, Peters VP, Voskuyl MJ, et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: a cross-sectional study. Ann Rheum Dis. 2009 Sep; 68(9):1395-400. doi: 10.1136/ard.2008.094151. Epub 2008 Aug 12.

Nielen MM, van Sijl AM, Peters MJ, et al. Cardiovascular disease prevalence in a primary care cohort of individuals with inflammatory arthritis, diabetes, and osteoarthritis: a comparative cross-sectional study. Arthritis Rheum. 2010;62 suppl 10: 2211.

Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther. 2005;7(5):R984-91. Epub 2005 Jun 29.

Douglas KM, Pace AV, Treharne GJ, et al. Excess recurrent cardiac events in rheumatoid arthritis patients with acute coronary syndrome. Ann Rheum Dis. 2006 Mar;65(3): 348-53. Epub 2005 Aug 3.

Sö dergren A, Stegmayr B, Lundberg V, et al. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis. 2007 Feb;66(2): 263-6. Epub 2006 Jul 19.

Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths rheumatoid arthritis. A population-based controlled study. Arthritis Rheum. 2005 Feb;52(2):402-11.

Maradit-Kremers H, Nicola PJ, Crowson CS, et al.Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005 Mar;52(3): 722-32.

Aubry MC, Maradit-Kremers H, Reinalda MS, et al. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007 May;34(5):937-42. Epub 2007 Mar 15.

Насонов ЕЛ. Антифосфолипидный синдром. Москва: Литтерра; 2004. 440 с. [Nasonov EL. Antifosfolipidnyi sindrom [Antiphospholipid syndrome]. Moscow: Litterra; 2004. 440 p.]

Насонов ЕЛ, Попкова ТВ. Кардиоваскулярные проблемы ревматологии. Научно-практическая ревматология. 2004;42(4):4-9. [Nasonov EL, Popkova TV. Cardiovascular problems of rheumatology. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2004;42(4):4-9. (In Russ.)]. doi: 10.14412/ 1995-4484-2004-794

Gazi IF, Boumpas DT, Mikhailidis DP, et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol. 2007 Jan-Feb; 25(1):102-11.

Teir J, Koduri G, Meadows A, et al. Letter to the editor (other). An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. Rheumatology (Oxford). 2008 Aug;47(8):1252-4.

doi: 10.1093/rheumatology/ken232. Epub 2008 Jun 23.

Sattar N, McCarey DW, Capell H, et al. Explaining how «high-grade» systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation.

Dec 16;108(24):2957-63.

Александрова ЕН, Новиков АА, Насонов ЕЛ. Высокочувствительные методы определения С-реактивного белка (обзор литературы). Клиническая лабораторная диагностика. 2004;(11):16–8. [Aleksandrova EN, Novikov AA,

Nasonov EL. Highly sensitive methods for the determination of C-reactive protein (literature review). Klinicheskaya laboratornaya diagnostika. 2004;(11):16–8. (In Russ.)].

Van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007 Feb; 66(2):184-8. Epub 2006 Jun 7.

Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of RA amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010 Dec;268(6):578-85. doi: 10.1111/j.1365-2796.2010.02260.x.

Goodson NJ, Symmons DP, Scott DG, et al. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year follow up study of a primary care-based inception cohort. Arthritis Rheum. 2005 Aug;52(8):2293-9.

Poole CD, Conway P, Currie CJ. An evaluation of the association between C-reactive protein, the change in C-reactive protein over one year, and all-cause mortality in chronic immune-mediated inflammatory disease managed in UK general practice. Rheumatology (Oxford). 2009 Jan;48(1):78-82. doi: 10.1093/rheumatology/ken415.

Jacobsson LT, Turesson C, Hanson RL, et al. Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum. 2001 May;44(5):1170-6.

Wаllberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol. 1999 Dec;26(12): 2562-71.

Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15;61(11):1580-5. doi: 10.1002/art.25009.

Goodson NJ, Wiles NJ, Lunt M, et al. Mortality on early inflammatory arthritis: cardiovascular mortality in seropositive patients. Arthritis Rheum. 2002 Aug;46(8): 2010-9.

Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009 Apr 15;61(4):419-24. doi: 10.1002/art.24390.

Solomon DH, Kremer J, Curtis JR, et al. Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis. 2010 Nov;69(11): 1920-5. doi: 10.1136/ard.2009.122226. Epub 2010 May 5.

Karlson EW, Chibnik LB, Tworoger SS, et al. Biomarkers of inflammation and development of rheumatoid arthritis in women from two prospective cohort studies. Arthritis Rheum. 2009 Mar;60(3):641-52. doi: 10.1002/art.24350.

Gerli R, Bartoloni Bocci E, Sherer Y, et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008 May;67(5):724-5. doi: 10.1136/ard.2007.073718.

Ross R. Atherosclerosis – an inflammatory disease. Am Heart J. 1999 Nov;138(5 Pt 2): S419-20.

Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol. 2003 Feb 6;91(3A):3A-6A.

Montecucco F, Mach F. Common inflammatory mediators orchestrate patho-physiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology (Oxford). 2009 Jan;48(1):11-22. doi: 10.1093/ rheumatology/ken395. Epub 2008 Oct 16.

Sattar N, Mclnnes IB. Vascular comorbidity in rheumatoid arthritis: potential mechanisms and solutions. Curr Opin Rheumatol. 2005 May;17(3):286-92.

Tedgui A, Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 2001 May 11;88(9):877-87.

Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008 Nov;118(11):3537-45. doi: 10.1172/JCI36389.

Full LE, Ruisanchez C, Monaco C. The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther. 2009;11(2):217. doi: 10.1186/ar2631. Epub 2009 Apr 3.

Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med. 2008 Oct;121(10 Suppl 1):S21-31. doi: 10.1016/j.amjmed.2008.06.014.

Pasceri V, Yeh ET. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation. 1999 Nov 23;100(21):2124-6.

Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006 Apr;86(2):515-81.

Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: национальное руководство. Москва: Гэотар-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, redaktory. Revmatologiya: natsional'noe rukovodstvo [Rheumatology: national guidelines]. Moscow: Geotar-Media; 2008. 720 p.]

Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb 11;340(6): 448-54.

Woods A, Brull DJ, Humphries SE, et al. Genetics of inflammation and risk of coronary artery disease: the central role of interleukin-6. Eur Heart J. 2000 Oct;21(19): 1574-83.

Rattazzi M, Puato M, Faggin E, et al. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens. 2003 Oct;21(10):1787-803.

Dixon WG, Symmons DP. What effects might anti-TNFtreatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFin cardiovascular pathophysiology. Ann Rheum Dis. 2007 Sep;66(9):1132-6. Epub 2007 Jan 24.

Kerekes G, Soltesz P, Der H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol. 2009 Jun;28(6):705-10.

doi: 10.1007/s10067-009-1095-1. Epub 2009 Mar 25.

Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008 Dec 15;59(12): 1821-4. doi: 10.1002/art.24308.

Raterman HG, Han NM, et al. Rituximab alters the HDL particle from a pro-inflammatory property in good responding rheumatoid arthritis patients. Arthritis Rheum. 2010;62 (suppl.10):332

Насонов ЕЛ, Каратеев ДЕ. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клиническая фармакология и терапия. 2006;(1):55-8. [Nasonov EL, Karateev DE. Prospects of application of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis. Klinicheskaya farmakologiya i terapiya. 2006;(1):55-8. (In Russ.)].

Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev. 2005 Apr;204:55-73.

Hochberg MC, Westhovens R, Aranda R, et al. Long-term safety of abatacept: Integrated analysis of clinical program data of up to 7 years of treatment. Ann Rheum Dis. 2010;69(10):S1. Abstract 390. ACR/ARHP Annual Scientific Meeting

Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007277. doi: 10.1002/ 14651858.CD007277

Jin T, Bokarewa M, Amu S, Tarkowski A. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol. 2009 May-Jun; 27(3):491-4.

Raterman HG, Levels H, Voskuyl AE

et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis. 2013 Apr;72(4):560-5. doi: 10.1136/ annrheumdis-2011-201228. Epub 2012 May 15.

Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141. doi: 10.1186/ar3455

Curtis JR, Perez-Gutthann S, Suissa S, et al. Actemra Pharmacoepidemiology Board. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum. 2015 Feb;44(4):381-8. doi: 10.1016/j.semarthrit.2014.07.006. Epub 2014 Jul 27.

Zhang J, Xie F, Yun H, et al. Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1813-8. doi: 10.1136/annrheumdis-2015-207870

Mathieu S, Couderc M, Glace B, et al. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics. 2013;7:259-64. doi: 10.2147/BTT.S52003. Epub 2013 Dec 2.

Ursini F, Russo E, Letizia Hribal M, et al. Abatacept improves whole-body insulin sensitivity in rheumatoid arthritis: an observational study. Medicine (Baltimore). 2015 May;94(21): e888. doi: 10.1097/MD.0000000000000888.

Gremese E, Carletto A, Padovan M, et al; Gruppo Italiano di Studio sulle Early Arthritis (GISEA). Obesity and reduction of the response rate to anti-tumor necrosis factor in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken). 2013 Jan;65(1):94-100.

doi: 10.1002/acr.21768.

Iannone F, Courvoisier DS, Gottenberg JE, et al. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the pan-European registry collaboration for abatacept (PANABA). Clin Rheumatol. 2017 Apr;36(4):773-779.

doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

Nü lein HG, Alten R, Galeazzi M., et al. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord. 2015 Jul 30;16: 176. doi: 10.1186/s12891-015-0636-9.

Weinblatt ME, Moreland LW, Westhovens R, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013 Jun; 40(6):787-97. doi: 10.3899/jrheum.120906. Epub 2013 Apr 15.

Ajeganova S, Humphreys JH, Verheul MK, et al.Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. Ann Rheum Dis. 2016 Nov; 75(11):1924-1932. doi: 10.1136/annrheumdis-2015-208579. Epub 2016 Jan 12.

Lоpez-Longo FJ, Oliver-Minarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009 Apr 15;61(4):419-24. doi: 10.1002/art.24390.

Emery P, Burmester GR, Bykerk VP, et al. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015 Jan;74(1):19-26.

doi: 10.1136/annrheumdis-2014-206106. Epub 2014 Nov 3.

Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014 Apr;41(4):666-72. doi: 10.3899/jrheum.130905. Epub 2014 Mar 1.

The authors declare that there are no conflicts of interest present.